102 filings
8-K
KDMN
Kadmon Holdings, Inc.
9 Nov 21
Sanofi completes acquisition of Kadmon
5:16pm
8-K
KDMN
Kadmon Holdings, Inc.
5 Nov 21
Submission of Matters to a Vote of Security Holders
5:06pm
8-K
KDMN
Kadmon Holdings, Inc.
4 Nov 21
Kadmon Provides Business Update and Reports Third Quarter 2021 Financial Results
8:06am
8-K
KDMN
Kadmon Holdings, Inc.
27 Oct 21
Other Events
9:49pm
8-K
KDMN
Kadmon Holdings, Inc.
21 Oct 21
Other Events
6:03am
8-K
4s2xkss
8 Sep 21
Sanofi to acquire Kadmon to further strengthen growth of transplant business
6:15am
8-K
ufy6mec
5 Aug 21
Kadmon Provides Business Update and Reports Second Quarter 2021 Financial Results
4:07pm
8-K
6t9a2
19 Jul 21
Other Events
4:05pm
8-K
ervgoygp aggpkm
12 May 21
Submission of Matters to a Vote of Security Holders
4:27pm
8-K
gigkv9ld4jhph2a33k85
6 May 21
Kadmon Provides Business Update and Reports First Quarter 2021 Financial Results
5:06pm
8-K
s58g rioy
1 Apr 21
Other Events
4:01pm
8-K
nmqaq061gb2wl1c0j3a
10 Mar 21
Kadmon Announces U.S. FDA has Extended the Review Period for Belumosudil in Chronic Graft-Versus-Host Disease
4:16pm
8-K
cc1zu5i
4 Mar 21
Kadmon Provides Business Update and Reports Fourth Quarter 2020 Financial Results
4:02pm
8-K
9nymee8x35eaq53yqgt
16 Feb 21
Entry into a Material Definitive Agreement
4:11pm
8-K
2rp3v w8cvpq
10 Feb 21
Kadmon Announces Proposed $150 Million Convertible Senior Notes Offering with Capped Call Transactions
4:00pm
8-K
k0c3wz6whcmpdi0etn
12 Jan 21
Departure of Directors or Certain Officers
4:16pm
8-K
iivz4
7 Dec 20
Kadmon Announces 12-Month Data from Pivotal Trial of Belumosudil for cGVHD at the 62nd ASH Annual Meeting
8:02am
8-K
h2wx6nfwra8
30 Nov 20
Kadmon Announces FDA Acceptance of NDA for Belumosudil in Patients with Chronic Graft-Versus-Host Disease
8:51am
8-K
7jb86r slm0c
5 Nov 20
Kadmon Provides Business Update and Reports Third Quarter 2020 Financial Results
4:21pm
8-K
refr2cvs0s 75z9eh
13 Oct 20
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:19pm